Table 1.
Description of cohort
| Category | Feature | Control (N = 18) | SLE (N = 51) | p. value |
|---|---|---|---|---|
| Age | mean (± sd) | 42.06 (15.65) | 41.14 (12.35) | 0.823 |
| Gender | Female, N (%) | 18 (100) | 51 (100) | 1 |
| Ethnicity | Hispanic/Latino, N (%) | 4 (22.2) | 23 (45.1) | 0.071 |
| Race | Asian, N (%) | 1 (5.6) | 12 (23.5) | 0.132 |
| Black or African American, N (%) | 6 (33.3) | 12 (23.5) | ||
| White, N (%) | 10 (55.6) | 27 (52.9) | ||
| More than one race, N (%) | 1 (5.6) | 0 (0) | ||
| Genotype | Homo ancestral, N (%) | 4 (22.2) | 12 (23.5) | 0.993 |
| Hetero variant, N (%) | 8 (44.4) | 22 (43.1) | ||
| Homo variant, N (%) | 6 (33.3) | 17 (33.3) | ||
| SLE Only | ||||
| N available | N (%) | Dose (± sd) | ||
| Medication | Prednisone, N (%), mg | 51 | 12 (23.5) | 6.88 (3.04) |
| Hydroxychloroquine, N (%), mg | 51 | 41 (80.4) | 351.22 (84.03) | |
| Azathioprine, N (%), mg | 51 | 5 (9.8) | 85 (33.54) | |
| Mycophenolate mofetil N (%), mg | 51 | 13 (25.5) | 2269.23 (753.20) | |
| Methotrexate, N (%), mg | 51 | 2 (3.9) | 13.75 (8.84) | |
| Benlysta, N (%), IV | 51 | 4 (7.8) | NA | |
| SELENA SLEDAI Domains | Seizure | 51 | 0 (0) | |
| Psychosis | 51 | 0 (0) | ||
| Organic brain syndrome | 51 | 0 (0) | ||
| Visual disturbance | 51 | 0 (0) | ||
| Cranial nerve disorder | 51 | 0 (0) | ||
| Lupus headache | 51 | 0 (0) | ||
| Cerebrovascular accident | 51 | 0 (0) | ||
| Vasculitis | 51 | 0 (0) | ||
| Arthritis | 51 | 2 (4.1) | ||
| Myositis | 51 | 0 (0) | ||
| Hematuria | 50 | 4 (8.0) | ||
| Proteinuria | 51 | 13 (25.5) | ||
| Pyuria | 51 | 3 (5.9) | ||
| Rash | 51 | 8 (15.7) | ||
| Alopecia | 51 | 4 (7.8) | ||
| Mucosal ulcers | 51 | 0 (0) | ||
| Pleurisy | 51 | 0 (0) | ||
| Pericarditis | 51 | 0 (0) | ||
| Low complement | 51 | 25 (49) | ||
| Increased DNA binding | 49 | 23 (46.9) | ||
| Fever | 51 | 0 (0) | ||
| Thrombocytopenia | 50 | 3 (6) | ||
| Leukopenia | 51 | 5 (9.8) | ||
| SLEDAI Total | mean (± sd) | 51 | 4.24 (4.12) | |
| Predominant Disease Category | Active lupus nephritis, N (%) | 47 | 13 (27.7) | |
| Active musculoskeletal disease, N (%) | 47 | 2 (4.3) | ||
| Predominately active cutaneous disease, N (%) | 47 | 4 (8.5) | ||
| Predominately hematologic activity, N (%) | 47 | 7 (14.9) | ||
| Clinically inactive disease and either ds-DNA or low complement N (%) | 47 | 13 (27.7) | ||
| Clinically and serologically inactive disease, N (%) | 47 | 8 (17) | ||
Descriptive characteristics of the SLE and control cohort. In addition, for the SLE cohort, ACR criteria, SLEDAI domains, medication usage, predominant disease category and progression status are also included. Percentages are based on available assessment data